Following the highly publicized clinical failure of AstraZeneca’s Wainua, Alnylam Pharmaceuticals has urged the public to exercise restraint, noting that more data is needed to confirm if its own competing medication will prove equally useless.
While preliminary observational data indicates a strong correlation between AstraZeneca’s clinical disaster and the likelihood of Alnylam facing a similar fate, independent researchers emphasize that correlation does not equal causation. Alnylam representatives have spent the week stressing that their specific compound is structurally distinct, meaning it possesses a highly differentiated mechanism through which it could eventually fail to treat heart disease.
Experts caution against drawing sweeping conclusions from a single cohort of disappointed investors. Medical statisticians have pointed out that the AstraZeneca trial was halted due to a specific, localized lack of efficacy, whereas Alnylam’s phase three trials are still ongoing and could potentially yield a completely different, statistically significant lack of efficacy if allowed to run their full course.
We simply do not have the sample size yet to definitively declare Alnylam’s pipeline a total loss.
The company recently circulated a pre-print study suggesting that its own heart disease therapy demonstrated a marginally lower risk factor for immediate trial collapse when adjusted for the placebo effect. However, a peer-reviewed editorial in a recent JAMA paper noted that these findings were largely self-reported and that patients should not alter their baseline pessimism without first consulting a primary care physician.
The FDA has consequently issued updated guidance advising cardiovascular patients to maintain their current skepticism regimen. Health officials added that until long-term longitudinal data is published, individuals should hold off on assuming any experimental biopharmaceutical will save them, as the prevailing literature strongly associates unbridled hope with adverse psychological events.